Navigation Links
Inverness Medical Innovations Announces Second Quarter 2008 Results
Date:7/29/2008

$(1.17) $0.25

Diluted $(1.17) (i) $0.24 (k)

Weighted average common shares -

basic 46,671 46,671

Weighted average common shares -

diluted 46,671 (i) 48,512 (k)

(a) In calculating net income or loss on an adjusted cash basis, the

Company excludes from net income or loss (i) certain non-cash charges,

including amortization expense and stock-based compensation expense, (ii)

non-recurring charges and income, and (iii) certain other charges and

income that have a significant positive or negative impact on results yet

do not occur on a consistent or regular basis in its business. In

determining whether a particular item meets one of these criteria,

management considers facts and circumstances that it believes are

relevant. Management believes that excluding such charges and income from

income or loss allows investors and management to evaluate and compare the

Company's operating results from continuing operations from period to

period in a meaningful and consistent manner. Due to the frequency of

their occurrence in its business, the Company does not adjust net income

or loss for the costs associated with litigation, including payments made

or received through settlements. It should be noted that "net income or

loss on an adjusted cash basis" is not a standard financial measurement

under accounting principles generally accepted in the United States of

America ("GAAP") and should not be considered as an alternative to net

income or loss or cash flow from operating activities, as a measure of

liquidity or as an indicator of operating performance or any measure of

performance derived in accordance with GAAP.

(b) Amortizati
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  The full interim results will be presented ... and IGF Society, being held October 15-18, 2014, ...
(Date:9/16/2014)... September 16, 2014 BCC Research ... FOR STEM CELLS , the global market for stem ... by 2018, with a five-year compound annual growth rate ... in the Americas with growth projections of $2.2 billion ...      (Logo: http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other potential ...
(Date:9/16/2014)... 2014 RENU 28, the world's first and ... available for purchase in Australia and New Zealand in mid-August ... September 16th. The tour will make stops in Brisbane on ... the 18th, Sydney on the 20th, and Melbourne on the ... New Zealand and to educate people about the new product ...
(Date:9/15/2014)... , Sept. 15, 2014   Global Science ... of scientific products and services for satellite and ... Solution for Integrated Services (OASIS) from the General ... was selected to provide the government best-value solutions ... Business (SB) category in Pool 4. The OASIS ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3
... Anesiva,Inc. (Nasdaq: ANSV ) announced today the ... directors. Mr. Janney previously served on Anesiva,s,board from November ... following the merger of Anesiva and AlgoRx Pharmaceuticals., ... of directors,and we are very pleased to welcome him ...
... Inc.,today announced that Edward L. Jacobs, president and ... medical officer,will present an update of the company,s ... Feb. 13, 2008, at the BIO CEO & ... will include information about Semafore,s lead product,candidate, SF1126, ...
... Diagnostic Imaging,International Corp. (OTCBB: DIIG) announced today that ... imaging clinics for acquisition., Following the Company,s ... of profitable operating clinics as well as open ... begun its diligence review on clinics that have,been ...
Cached Biology Technology:Anesiva Appoints Daniel Janney to Board of Directors 2Anesiva Appoints Daniel Janney to Board of Directors 3Semafore to Present at BIO CEO & Investor Conference 2Diagnostic Imaging - Acquisitions - OTCBB: DIIG 2
(Date:9/16/2014)... Fla. , Sept. 16, 2014  Cross ... identity management solutions, announced today the launch of ... to authenticate the identity of an individual using ... Android-based Verifier Sentry rapidly reads credential documents with ... ID by matching the biometric to a live ...
(Date:9/15/2014)... 15, 2014) The so-called central dogma of ... long provided a simplified explanation for how genetic ... , In reality, of course, the process ... articulated nearly 60 years ago by Nobel Laureate ... For one, there are multiple types of RNA, ...
(Date:9/15/2014)... research has determined that a single group of microorganisms ... B12 production in the oceans, with implications for the ... B12 is an essential molecule required by most life ... relatively small group of microorganisms because it is so ... key role in maintaining the brain and nervous systems, ...
Breaking Biology News(10 mins):Cross Match Launches New Identity Management Handheld Solution 2Scientists discover RNA modifications in some unexpected places 2Researchers discover new producer of crucial vitamin 2
... Johnson & Johnson today announced that Axel Ullrich, Ph.D., ... Max Planck Institute of Biochemistry in Germany, whose discoveries ... , is the winner of the 2009 Dr. Paul ... of world-renowned scientists selected Dr. Ullrich, who on September ...
... mice responsible for repairing DNA strands damaged by oxidation ... that such stress contributes to the development of cancer. ... DNA Repair by researchers at the National Institute ... University (OHSU) and the New York University School of ...
... time, scientists have shown that chromosomal abnormalities are present ... produced by young, fertile couples. Ms Evelyne Vanneste, a ... the University Fertility Center, Leuven University, Belgium, told the ... Reproduction and Embryology today (Wednesday July 1), that the ...
Cached Biology News:Axel Ullrich named winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2Genetically engineered mice yield clues to 'knocking out' cancer 2Chromosomal problems affect nearly all human embryos 2Chromosomal problems affect nearly all human embryos 3
... rapid analytical to medium scale affinity purification ... vectors. Sufficient reagents are provided for purification ... under native or denaturing conditions. Crude samples ... retains STag fusion proteins. After unbound proteins ...
Request Info...
... Epitope: aa 16-25 of human GSK3 alpha. ... Storage: Store vial at -20 C prior to opening. ... aliquot contents and freeze at -20 C or below. ... Other Sub-Family: not assigned-Other ...
... Physical form: Essentially sulfate-free, powder ... Preparation Unit Definition: One ... D -fructose 6-phosphate to ... pH 7.4 at 25 C. ...
Biology Products: